Convalescent plasma treatment

BIOLOGICAL2 trials

Sponsors

Clinical Research Management, Inc., National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

Conditions

COVID-19Ebola Virus Disease

Phase 2

Convalescent Plasma as Adjunct Therapy for COVID-19

National Institute of Health Research and Development, Ministry of Health Republic of IndonesiaCOVID-19

Start: 2020-12-01End: 2021-12-31Target: 364Updated: 2021-06-02

Unknown Phase

Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment

Clinical Research Management, Inc.Ebola Virus Disease

Start: 2014-11-30End: 2015-06-30Target: 70Updated: 2015-01-07

Related Papers

Anti-ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with ebola virus disease

UNC Libraries2020-08-18

Anti–Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease

The Journal of Infectious Diseases2018-04-0337 citations

Ebola clinical trials: Five lessons learned and a way forward

Clinical Trials2016-01-1427 citations